Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors

NCT07258160 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Soochow University

Phase

Phase 2

Started

2025-12-01

Last updated

2026-01-09

Condition(s) studied

Solid CancerLymphopenia

Investigational drug(s) / intervention(s)

PRaG-1Placebo

PRaG-1: The PRaG-1 cordycepin tablets used in this clinical study were produced by Shengmingyuan Company, which is affiliated with the National Bioprocess Engineering Research Center at Nanjing Tech University. The tablets are oral formulations containing 200 mg of cordycepin per tablet and have obtained national food production approval. The production license number is: SC11332019200201.

Placebo: Placebo

Study summary

The goal of this clinical trial is to evaluate the effectiveness of PRaG-1 in improving CD8+ lymphocytopenia in patients with solid tumors who are tumor-free for more than six months after completing radiotherapy and/or chemotherapy. It will also assess the safety of PRaG-1 Cordycepin in these patients. The main questions it aims to answer are:

Does PRaG-1 increase CD8+ lymphocyte counts by more than 25% in this patient population? Does the effect of PRaG-1 maintain when treatment is discontinued? What are the safety and tolerability profiles of PRaG-1 during and after the treatment period? Participants will receive open-label PRaG-1 (one tablet in the morning and one in the evening) for 14 days, and those who show a response (CD8+ lymphocytes increase by more than 25%) will enter a 14-day randomized withdrawal period, where they will be assigned to continue PRaG-1 or switch to a placebo.

Throughout the study, participants will:

Have their peripheral blood lymphocyte subpopulations tested at baseline and on Days 7 and 14 Undergo safety monitoring for adverse events according to CTCAE 5.0 criteria Provide information on their quality of life during the treatment period Researchers will compare the outcomes of those who continue PRaG-1 to those who receive a placebo to determine if the observed improvement in CD8+ lymphocytes is sustained, which would indicate that the drug is effective in maintaining immune response.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age ≥ 18 years; 2. Participants with solid malignant tumors, with confirmed pathological diagnosis or medical history; they have completed radiotherapy and/or chemotherapy more than six months ago; and peripheral blood CD8+ absolute count (blood drawn before 10:00 AM) below the lower reference limit (LRL); 3. No treatment with immunomodulatory or immunosuppressive agents within the past 2 weeks prior to enrollment; 4. ECOG performance status score of 0-1, with an estimated life expectancy of ≥ 3 months; 5. AST and ALT ≤ 3.0 times the upper limit of normal (ULN) within one week prior to study enrollment; serum creatinine ≤ 2 times ULN; 6. Ability to understand the study and voluntarily provide written informed consent. Exclusion Criteria: 1. History of uncontrolled epilepsy, central nervous system (CNS) disease, or mental disorders, as determined by the investigator to be clinically significant and potentially interfere with the participant's ability to provide informed consent or comply with medication; 2. Significant (i.e., active) cardiovascular disease, including symptomatic coronary heart disease, congestive heart failure classified as New York Heart Association (NYHA) Class II or worse, or serious arrhythmias requiring pharmacological intervention, or history of myocardial infarction within the past 12 months; 3. Known active serious infections, or in the investigator's opinion, presence of major hematological, renal, metabolic, gastrointestinal, or endocrine dysfunction, or other serious, uncontrolled comorbidities; 4. History of allergy to fungi, or to any of the following components: Cordyceps militaris extract powder, D-mannitol, maltitol, microcrystalline cellulose, or magnesium stearate; 5. History of immunodeficiency, including HIV positive status, or diagnosis with other acquired or congenital immunodeficiencies, or a history of organ transplantation, or immunological disorders requiring long-term oral corticosteroid treatment; 6. Acute gout flare 7. Any other condition deemed unsuitable for enrollment by the investigator.

Primary outcome measure(s)

Percentage Change in CD8+ Proportion of Participants with >25% Decline in CD8+ Lymphocyte During the Withdrawal Period (measured by flow cytometry) — 2 weeks

Trial sites (1)

Facility	City	Region	Status
The Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu	Recruiting

More Second Affiliated Hospital of Soochow University trials in China

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC Recruiting

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH) Recruiting

DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes Starting soon

Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor Recruiting

Light Therapy in Parkinson's Disease Recruiting

Other trials for the same condition

A Study of HS-20124 in Patients with Advanced Solid Tumors Recruiting

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors Active, not recruiting

A Study of AK138D1 in Advanced Malignant Tumors Recruiting

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07258160 on ClinicalTrials.gov ↗ ← All trials in China